Austria’s Themis Bioscience has raised 40 million euros ($44 million) in a series D financing round led by new investors Farallon Capital and Hadean Ventures, with additional money from existing investors including Merck & Co. 18 September 2019
US biotech firm Amplyx Pharmaceuticals has executed an exclusive worldwide license agreement with Swiss pharma giant Novartis under which Amplyx has acquired the rights to the Phase II anti-BK virus (BKV) monoclonal antibody, MAU868, for the treatment and prevention of BKV disease. 16 September 2019
Astellas Venture Management and Mission Bay Capital BioLabs (MBC BioLabs) are supporting pre-clinical scientific research with a "Golden Ticket" initiative. 12 September 2019
NHS England and US biotech firm BioMarin have reached agreement that will now make Brineura (cerliponase alfa) available for eligible children in England with the fatal, progressive condition, Late Infantile Batten Disease (CLN2). 11 September 2019
Shanghai’s I-Mab Biopharma and Junshi Biosciences have inked a deal to evaluate a combination therapy of I-Mab's TJD5, a CD73 antibody, with Tuoyi (toripalimab), a checkpoint inhibitor. 10 September 2019
German contract development and manufacturing company ProBioGen today announced the closing of a license agreement with pharma major Bayer for the GlymaxX® Technology. 10 September 2019
UK-based flu specialist Seqirus has said it will manufacture its cell-based influenza vaccine Flucelvax Tetra using cell-based technology for all four strains each season. 9 September 2019
Ireland-incorporated Endo International has submitted a Biologics License Application (BLA) to the US Food and Drug Administration for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks. 7 September 2019
Genetic medicines company Passage Bio has raised $110 million in a series B financing round led by Access Biotechnology, with participation from existing investors. 6 September 2019
Swiss pharma giant Novartis has gained European Commission approval for Lucentis (ranibizumab) in preterm infants with retinopathy of prematurity (ROP), which has come through much sooner than the company expected. 6 September 2019
Californian biotech Dendreon Pharmaceuticals has presented real-world data from patients nearly four years after they were treated with its US-approved immunotherapy Provenge (sipuleucel-T). 5 September 2019
The UK BioIndustry Association (BIA) has welcomed the announcement that the National Health Service (NHS) will be providing cell and gene therapies to treat patients with inherited retinal dystrophies. 5 September 2019
French biotech Genfit has appointed Pascal Prigent as chief executive. Former CEO and co-founder Jean-François Mouney will remain chairman of the board. 4 September 2019
Mats Blom, the chief financial officer (CFO) of Zealand Pharma for nine years, has taken up the same role at the Dutch biotech company, NorthSea Therapeutics. 4 September 2019
The Japanese launch of Collategene (beperminogene perplasmid) is imminent, after drugmaker Mitsubishi Tanabe Pharma secured a National Health Insurance (NHI) drug price listing for the product. 4 September 2019
The USA’s Institute for Clinical and Economic Review (ICER) on Friday posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value treatments for crizanlizumab and voxelotor, both of which will be indicated for sickle cell disease. 31 August 2019
The Roche unit Chugai has filed for an additional indication of Kadcyla (trastuzumab emtansine) as adjuvant therapy in patients with HER2-positive early breast cancer in Japan. 30 August 2019
US drugmaker AbbVie has admitted defeat with Rova-T (rovalpituzumab tesirine) – a drug that it acquired in its $5.8 billion takeover of Stemcentrx in 2016. 29 August 2019
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024